Microbot Medical Increases Presence in the EU with the Addition of Greece-based Key Opinion Leader Stavros Spiliopoulos, MD, PhD, EBIR-ES, FCIRSE, to its Scientific Advisory Board
HINGHAM, Mass., March 13, 2023 (GLOBE NEWSWIRE) — Microbot Medical Inc. (Nasdaq:MBOT), which continues to experience a rising interest in the LIBERTY ® Robotic System, the first single-use endovascular robotic system, today announced that Stavros Spiliopoulos, MD, PhD, EBIR-ES, FCIRSE, a key opinion leader (KOL) from Greece, has joined the Company’s Scientific Advisory Board (SAB). The addition of Dr. Spiliopoulos, an Associate Professor of Interventional Radiology at Attikon University General Hospital of Athens, further enhances the Company’s EU presence, and his participation will be invaluable as the Company progresses its regulatory and commercialization plans for the LIBERTY® Robotic System.
Related news for (MBOT)
- Midday Market Wrap: Spider Silk Strength, Robotics Surge & Autonomous Acceleration Fuel the Afternoon Trade
- Microbot Medical® Receives FDA 510(k) Clearance for Its LIBERTY® Endovascular Robotic System
- 24/7 Market News Snapshot 08 September, 2025 – Microbot Medical, Inc. Common Stock (NASDAQ:MBOT)
- MoBot alert highlights: NASDAQ: OCTO, NASDAQ: AREB, NASDAQ: CDT, NASDAQ: ACRV, NASDAQ: MBOT (09/08/25 06:00 AM)
- MoBot alert highlights: NASDAQ: AREB, NASDAQ: CDT, NASDAQ: OCTO, NASDAQ: ACRV, NASDAQ: MBOT (09/08/25 05:00 AM)